Drugs giant GlaxoSmithKline has joined forces with US non-profit organisation
PATH (Program for Appropriate Technology in Health) to develop its malaria
vaccine. GSK’s vaccine was 70 per cent effective in protecting people against
malaria in preliminary trials—the best result for any malaria vaccine so
far. PATH will pay GSK $6.7 million to develop it further for use in
young children, who are at highest risk of dying from malaria. GSK hopes to have
a vaccine by 2008, which it plans to distribute in Africa and other endemic
areas “at a very reasonable price”.
To continue reading, today with our introductory offers
Advertisement
More from 91av
Explore the latest news, articles and features
Popular articles
Trending 91av articles
1
Red-light therapy does have health benefits but not the ones you think
2
Woman in cancer remission without treatment in highly unusual case
3
A lost ancient script reveals how writing as we know it really began
4
PCOS postpones perimenopause and allows pregnancies at older ages
5
Man destined for Alzheimer's may have been saved by accidental therapy
6
Extinct relative of koalas discovered in Western Australia
7
Where has the deadly hantavirus come from and how does it spread?
8
Pressure from individual particles measured for the first time
9
The greatest David Attenborough documentaries you really need to watch
10
300-year-old experiment could become world's best dark matter detector
